Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

Winners of Digital RESI June 2021 Innovator’s Pitch Challenge (IPC)

17 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Digital Redefining Early Stage Investments (RESI) June ended on a high note last week, again providing a valuable platform for early-stage life science companies and investors/strategic partners to connect and start dialogue.

This RESI also featured the largest number of Innovator’s Pitch Challenge companies, with almost fifty companies participating. Each company was assigned to one of ten live Q&A sessions featuring investors and industry partners, based on sector/technology.

Attendees voted for their favorite companies throughout the three days of the conference. Check out the winners below!

1st Place – Throne Biotechnologies

Throne is an American therapeutics company aimed at commercializing a novel stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. The patented technology is recognized as the leading “practical cure project” for type 1 diabetes among 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like treatment that fundamentally “resets” a patient’s immune system and corrects the underlying autoimmunity. 200+ patients between the ages of 3 and 70 have been treated in 10 years of clinical research in Spain, China, and US. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy. Many patients reduced insulin dosing and some have become insulin independent. This technology has been successfully tried in more than 10 autoimmune diseases including alopecia, lupus, fibrosis, and scleroderma. This therapy is ready to use and is approved to begin three FDA phase 2 clinical trials (type 1 diabetes, alopecia areata, COVID-19). Throne is looking to raise $5M to complete US FDA phase 2 through to commercialization. Throne is open to partnerships, joint ventures, investments, and license arrangements.

2nd Place – Praetego

Praetego is a pre-clinical stage pharmaceutical company with a mission to improve the health and longevity of diabetic patients. Praetego is developing novel small molecules (Amadorins) to alleviate serious diabetic complications, starting with peripheral neuropathy. Amadorins are first-in-class molecules able to inhibit a primary driver of diabetic microvascular disease and are derived from a clinically proven prototype.

3rd Place – Nano PharmaSolutions

A proprietary drug delivery nanotechnology that generates poorly soluble drugs as nanoparticles for better bioavailability. Our NanoTransformer(TM) technology can generate drug nanoparticles through phase transfer method without using any chemicals or solvent. We work with (1) preclinical stage drug developers for animal study formulations and (2) innovative generic companies for generic nanodrug development. We are at revenue stage and our revenue forecast is $150M in 2026 (our target exit time frame).

Congratulations to each of the winners, who have received free tickets to future RESI conferences to boost their fundraising efforts. Thank you to all finalists, judges, and attendees who make the IPC an exciting and powerful part of RESI! Interested in joining a future IPC? Applications are open for RESI Partnering Week September, featuring three separate RESI conferences! Select the logos below to learn more!

Apply for RESI IPC
Sept.13-15
Apply for RESI AI IPC
Sept.16-17
Apply for RESI Longevity IPC
Sept.16-17

Super early bird rates apply until July 9. Sign up now to save $100!

Panels at RESI Partnering Week September 13-17, 2021

17 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

RESI Partnering Week returns September 13-17 and attendees can save $100 when they register by July 9! RESI Partnering Week is a five-day digital partnering experience connecting early-stage entrepreneurs in drugs, devices, diagnostics, and digital health with active investors who are a fit for their product and stage of development.

The RESI creators at Life Science Nation (LSN) understand that partnering is a multi-faceted process that takes time and commitment to yield fruitful relationships that turn into strategic partnerships. We offer several programs for attendees to take advantage of in order to optimize their experience, including our interactive panels that feature prominent life science and healthcare investors, as well as fundraising executives with their own tales from the road.

resi-sept-logo

  • Angels & Family Offices
  • Asia Cross Border
  • Big Pharma
  • Corporate VC
  • Medical Devices
  • Mental & Behavioral Health
  • Seed Funds
  • Tales from the Road

resi-ai-sept

  • Healthcare Communications
  • Reproductive Wellness
  • Healthcare Systems and Infrastructure
  • Accelerated Pharmaceutical Development
  • Diagnostic Wearables
  • Precision Medicine

resi-longevity-sept

  • Social Isolation & Loneliness
  • Health & Home Care
  • Medical Accountability & Adherence
  • Sensory Wellness

Contact us to learn more about RESI Partnering Week and how we can tailor the experience to meet your partnering needs.

For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
International & MA (USA) West Coast (USA) East Coast (USA) & Canada Midwest (USA)
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!
Antoinette Lowre
Manager of Business Development
Schedule a call with me!

Amarex’s Success at RESI’s Service Provider Showcase

17 Jun

By Elizabeth Murphy, Manager of Business Development, LSN

Service Provider Showcase participant, Amarex Clinical Research joined Digital RESI on June 8-10 by hosting a dynamic workshop on Expediting U.S. FDA Submissions/Trial Initiations and Acceptance of Foreign Data by the U.S. FDA. The Amarex team put on a well-attended workshop helping early-stage entrepreneurs navigate the often-complicated processes working with the FDA. Of their experience with Digital RESI, the team said, “This virtual conference provided Amarex a fantastic opportunity to present in front of leading venture capitalists and pharma/biotech startups on top strategies to get products through the FDA clinical trials approval process. “

As a sponsor of the event, Amarex’s content received prominent placement on the 3-day event agenda, but also the partnering platform. Newcomers to the Digital RESI experience, the Amarex team said, “RESI’s platform provides the life sciences industry with innovative ways to network through their partnering program, allowing our team members to build new relationships with key executives. We look forward to participating in future RESI events.”

Digital RESI returns in September, as a part of RESI Partnering Week, alongside RESI AI and RESI Longevity. Learn more about the 5-day partnering experience and how your organization can take part in the sponsorship opportunities, reach more clients, and help them reach their goals.

For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
International & MA (USA) West Coast (USA) East Coast (USA) & Canada Midwest (USA)
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!
Antoinette Lowre
Manager of Business Development
Schedule a call with me!

RESI Partnering Week Returns September 13-17

10 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

RESI Partnering Week (RPW) returns September 13-17 for five days of match-based partnering, educational workshops, expert panels, innovative pitch sessions, and more!

RPW features a unique model made up of three days of Digital Redefining Early Stage Investments (RESI), followed by two days of targeted partnering and unique content designed specifically for age-tech and AI technology.

Get to know each event to see which are a fit for you! Super early bird rates are available until July 9, so register today to SAVE!

Redefining Early Stage Investments (RESI)

September 13-15, 2021

resi-sept-logoThe Redefining Early Stage Investments (RESI) conference series brings together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early-stage firms who seek seed, series A, and B funding.

RESI AI

September 16-17, 2021

resi-ai-septArtificial intelligence (AI) is rapidly reshaping the healthcare landscape and redefining what is possible in life science. RESI AI is a digital partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health to revolutionize healthcare. RESI AI features investors and entrepreneurs sharing their experiences in early-stage funding and what makes a successful partnership. This two-day digital conference provides the opportunity to meet and learn from experts, build relationships, and advance healthcare through the power of AI.

RESI Longevity

Co-Organized with Mary Furlong & Associates
September 16-17, 2021

resi-longevity-septThe aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. RESI Longevity is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. RESI Longevity brings fundraising startups together with investors in age-tech innovation to make deals in order that today’s seniors live longer, healthier lives.

Learn more about what to expect at each event and how you can get involved!

1:1 Partnering

handshack_icon

The investors attending RESI represent a huge pool of capital, and Life Science Nation (LSN)’s unique partnering system enables fundraising companies find the investors and strategic partners that are a best fit for their technology and stage of development.

  • Review profiles of other participants.
  • Schedule one-on-one and/or group meetings.
  • Build your customized conference schedule, from panels to presentations to partnering meetings

Investor Panels & Workshops

panels_icon_new

Panels and workshops highlight panelists who can provide their perspective on current trends, as well as valuable advice to fundraising start-ups. From big corporations to angel groups, and from established VCs to family offices, the panelists participating at RESI reflect LSN’s global investor network. Panels will be live-streamed, giving audience members a chance to get their questions answered in real-time.

Innovator’s Pitch Challenge

ipc_icon_new

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Apply for RESI IPC
Sept.13-15
Apply for RESI AI IPC
Sept.16-17
Apply for RESI Longevity IPC
Sept.16-17

Virtual Exhibit Hall

exhibitor hall

Exhibitors and sponsors will be featured on a dedicated page with a virtual exhibitor booth, showcasing their services and the value they can provide. Participating tech hubs can highlight their programs and constituent companies.

Digital RESI by the Numbers

10 Jun

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation’s (LSN) most recent Digital Redefining Early Stage Investments (RESI) conference is wrapping up today. Digital RESI June is proof that the digital model has worked and continues to add value to the early-stage fundraising ecosystem. This week’s event featured an exciting lineup of insightful panels with engaged audiences, live pitch sessions with eager and active investor judges, and educational workshops hosted by key industry leaders like the National Institutes of Health (NIH).

The success of Digital RESI is never clearer than when looking at the RESI Partnering Platform. Over the 3 days of the event, 1600+ meetings were booked, with some companies booking as many as 34 meetings. The chart shows the breakdown of the meetings taking place – three quarters of which are investors and companies connecting, either for the first time, or continuing an existing dialog.

Numbers don’t lie, and the Digital RESI conference series continues to prove the importance of a partnering-focused event in moving the needle forward in the early-stage funding ecosystem.

If you missed Digital RESI June, don’t worry! Registration is open for RESI Partnering Week, September 13-17. Super early bird rates apply until July 23, so sign up and save!

What to Do When the (RESI) Party Ends?

10 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

You’ve prepped your materials, done your research, messaged potential partners, booked meetings, delivered a pitch, sent your Thank-Yous… Now what? How do you make the most of your time at Digital RESI June after the curtain closes? Life Science Nation (LSN) has designed the Redefining Early Stage Investments (RESI) conference series around the reality of early-stage fundraising in life science. It’s a numbers game. LSN’s model works because it includes regular partnering events built on a match-based strategy, and the products and services fill in the gaps between events.

LSN’s database subscriptions utilize one-on-one interviews with our community, ensuring that the fundraising executive or investor has the latest information at their fingertips, providing a RESI-esque experience between the conferences. LSN databases are designed with the end user in mind and their goals of reaching strategic partners and technology assets that are a fit for their needs. Fundraising executives can find active investors who are a fit for their product and stage of development, and investors can source product pipelines, portfolio assets, licensing opportunities, and so much more.

Investor-database BD-Database

RESI is a unique experience, and the closest our attendees come is through our database subscriptions. Learn more about how they are enabled to meet your needs and contact a business development representative for a demo!

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) & Canada 
Greg Mannix
Vice President International Business Development
Book a Meeting!
Candice He
Director of Pacific Region & Global Investment Strategist
Book a Meeting!
Elizabeth Murphy
Manager of Business Development
Book a Meeting!

NIH’s Billion-Dollar SEED Fund Explained at Digital RESI June

3 Jun

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Join Dr. Matthew McMahon, Director of the NIH’s Small Business Education and Entrepreneurial Development (SEED) program, as he discusses how the NIH prioritizes early product development and offers resources to innovative entrepreneurs to help them succeed and save lives. The panel takes place Wednesday, June 9 at 1 PM EDT. You don’t want to miss this powerful collaboration and the opportunity to learn how the NIH is shaping the business landscape for early-stage technology like yours!

Your Partner in Driving Healthcare Returns

NIH has launched SEED to strategically align academic research resources, dedicated funding for small businesses, and business and product development expertise to help entrepreneurial scientists move their promising discoveries through the early product development pipeline. NIH’s Small Business Program, also known as America’s Seed Fund, provides over one billion dollars annually to small businesses to validate the potential healthcare potential of scientific discoveries and to test the feasibility of novel products and services resulting from these discoveries. This panel will highlight NIH’s strategic focus in early product development, resources and opportunities available to small business innovators, the SEED-sponsored technical and entrepreneurial advisory services, and will explore how building relationships with business, finance, and healthcare stakeholders help ensure these innovations will impact patients’ lives.

Matthew McMahon, PhD, Director, SEED, NIH

Small Business Education and Entrepreneurial Development (SEED) at NIH was recently established to accelerate scientific discoveries from bench to bedside. SEED builds upon NIH’s $1 billion/year Small Business Program by providing additional services to support a comprehensive translational research ecosystem. SEED coordinates a national network of proof-of-concept centers that support academic investigators to validate the potential health impacts of their scientific discoveries, improves the likelihood that promising technologies transition from academia to small businesses, and trains a biomedical workforce that is well-versed in product development and entrepreneurship. SEED also provides a host of professional advisory services, through a team of Entrepreneurs-in-Residence and life science industry veterans, designed to strengthen projects as they transition from discovery science to product development and provides the contacts in business, finance, and healthcare that are necessary to move projects from research and development toward patient access.

Matt has a diverse background in academia, biomedical small business, congressional policy, and NIH program development and management. He most recently served as the director of the National Heart, Lung, and Blood Institute’s Office of Translational Alliances and Coordination where his team assisted over 500 Small Business Program and 100 translational research program applicants and grantees annually. His team also developed a volunteer network of over 75 serial entrepreneurs, angel and venture capital investors, and medical device and drug development industry veterans that provided innovators with specialized product development and business assistance. Matt previously created and led the National Eye Institute’s Office of Translational Research to advance ophthalmic technologies through public-private partnerships with the pharmaceutical and biotechnology industries. His previous experience also includes service as the principal scientist for the bionic eye company Second Sight Medical Products and as a staff member on both the United States Senate and House of Representatives committees responsible for science, technology, and innovation policy. Matt holds a B.S. in Optical Engineering from the University of Rochester and a M.A and Ph.D. in Experimental Psychology from the University of California, San Diego.

Chris Sasiela, PhD, RAC, Senior Regulatory Specialist ,Innovator Support Team Lead, SEED, Office of Extramural Research, NIH

Dr. Sasiela has over a decade of experience providing support and consultation to academic innovators and small businesses engaged in therapeutic, device, and diagnostic development programs. As the Innovator Support Team Lead in SEED (Small business Education and Entrepreneurial Development) in the Office of Extramural Research at the National Institutes of Health, Chris coordinates the activities of a team of seasoned professionals with experience in product and business strategy, business development, fundraising, partnerships, reimbursement, and regulatory affairs. Chris is passionate about enabling NIH’s innovator community to progress their discoveries as far as science and human biology permit. Starting her career as a researcher, Chris worked in basic research at the University of Southern California and the University of Maryland, and in drug discovery, development, and improvement groups at Baxter, the Department of the Army, and the National Cancer Institute. Chris transitioned from a research to a regulatory career path via an Interagency Oncology Taskforce Fellowship at the US Food and Drug Administration. Continuing her regulatory career path at Social & Scientific Systems, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute, Chris deepened her experience working with product development researchers understand, develop, and execute regulatory plans to get their innovative technologies from ideas to first-in-human and beyond. She regularly conducts project-focused consultations, delivers educational seminars, and develops regulatory resources for internal and external audiences. Dr. Sasiela earned a bachelor’s degree in chemistry from Whittier College, a Ph.D. in Pharmaceutical Sciences from the University of Maryland, School of Pharmacy, and has maintained Regulatory Affairs Certification status from the Regulatory Affairs Professional Society since 2011.

Stephanie Fertig, HHS Small Business Program Lead, SEED, Office of Extramural Research (OER), NIH

Ms. Stephanie J. Fertig is the new HHS Small Business Program Lead in SEED (Small business Education and Entrepreneurial Development) at the National Institutes of Health (NIH). She currently oversees the Health and Human Services (HHS) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which includes the NIH SBIR and STTR programs. The HHS SBIR and STTR programs are congressionally mandated set-aside programs that provide over $1.2 billion dollars per year to small business concerns. Prior to joining SEED, she managed the SBIR and STTR Programs at the National Institute of Neurological Disorders and Stroke (NINDS). During her over 15 years at NIH she has led the development and implementation of multiple programs focused on small businesses and translational research. Ms. Fertig has a Bachelor of Science degree in Chemistry with a major in Physics from the University of Virginia and a Master of Business Administration from the University of Maryland’s Robert H. Smith School of Business.

John P. Sullivan, Entrepreneur In Residence, NIH

John Sullivan has been a leader in healthcare technology innovation throughout his career, with extensive experience in operating, investing in, developing and acquiring market-leading businesses. He currently serves as an Entrepreneur In Residence at the National Institutes of Health – promoting innovation and commercialization of technologies within NIH-funded life science ventures. Prior to the NIH, John worked with healthcare leaders such as Cardinal Health (VP, Strategy and Business Development) and Boston Scientific. He was a Partner with Foundation Medical Partners, a national healthcare venture capital firm with financial backing from the Cleveland Clinic. He also helped to start Molecular Staging Inc., a biotechnology tools company spun out of Yale University School of Medicine. Working with Yale University founders, he helped grow the company to over 100 employees, develop its product and service lines, and ultimately sell the company to Qiagen, a global life sciences company. He has served on the boards of directors of Semprus Biosciences (acquired, Teleflex), Coapt Systems (acquired, MicroAire), KEW Group, and Direct Flow Medical and held board observer roles at BridgePoint Medical (acquired, Boston Scientific) and Explorys (acquired, IBM). John earned a B.S. in Industrial Engineering degree with distinction from Stanford University and an M.B.A. from the Stanford University Graduate School of Business.

%d bloggers like this: